Patient satisfaction with treatments for moderate-to-severe plaque psoriasis in clinical practice
Open Access
- 22 November 2013
- journal article
- research article
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 170 (3), 672-680
- https://doi.org/10.1111/bjd.12745
Abstract
Background Treatment satisfaction among patients with moderate‐to‐severe psoriasis has not been studied and compared across treatments using a validated instrument. Objectives To assess patient‐reported satisfaction with systemic and phototherapy treatments for moderate‐to‐severe psoriasis in clinical practice and to correlate satisfaction with disease severity and quality‐of‐life measures. Methods This was a cross‐sectional study of 1182 patients with moderate‐to‐severe psoriasis in the Dermatology Clinical Effectiveness Research Network in the U.S.A. Patients receiving either topical therapies only; monotherapy with oral systemic therapies, biologics or narrowband ultraviolet B phototherapy; or combination therapy with biologics and methotrexate completed the Treatment Satisfaction Questionnaire for Medication version II. Results Median unadjusted overall satisfaction scores were highest for patients receiving biologic monotherapies, biologic–methotrexate combinations, or phototherapy (83·3); scores were lowest for those receiving topical therapies only or acitretin (66·7). In fully adjusted models, compared with patients receiving methotrexate monotherapy, those receiving adalimumab, etanercept, ustekinumab, phototherapy or adalimumab with methotrexate had significantly higher median overall satisfaction scores by 7·2–8·3 points, while those receiving topical therapies only had significantly lower overall satisfaction by 8·9 points. Adjusted convenience scores were lowest for patients receiving topical therapies only or infliximab. Modest but significant correlations were found between the overall satisfaction subscale and both the Psoriasis Area and Severity Index (ρ = −0·36, P < 0·001) and the Dermatology Life Quality Index (ρ = −0·47, P < 0·001). Conclusions Discernible differences were found in treatment satisfaction among therapies, particularly regarding treatment effectiveness and convenience. Further application of treatment satisfaction measures may inform treatment decisions and guideline development.Keywords
This publication has 42 references indexed in Scilit:
- Comparison between Two Generic Questionnaires to Assess Satisfaction with Medication in Chronic DiseasesPLOS ONE, 2013
- Comparative Effectiveness of Commonly Used Systemic Treatments or Phototherapy for Moderate to Severe Plaque Psoriasis in the Clinical Practice SettingArchives of Dermatology, 2012
- The Risk of Depression, Anxiety, and Suicidality in Patients With PsoriasisArchives of Dermatology, 2010
- Development and validation of a questionnaire on 'Satisfaction with dermatological treatment of hand eczema' (DermaSat)Health and Quality of Life Outcomes, 2010
- Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research DatabaseEuropean Heart Journal, 2009
- Determining the relative importance of patient motivations for nonadherence to topical corticosteroid therapy in psoriasisJournal of the American Academy of Dermatology, 2006
- Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasisJournal of the American Academy of Dermatology, 2006
- Prevalence and Treatment of Psoriasis in the United KingdomArchives of Dermatology, 2005
- A clinician's paradigm in the treatment of psoriasisJournal of the American Academy of Dermatology, 2005
- Traditional systemic treatments have not fully met the needs of psoriasis patients: Results from a national surveyJournal of the American Academy of Dermatology, 2005